Pre-Exposure Prophylaxis

Injectable cabotegravir administered every 8 weeks was associated with approximately nine times fewer HIV infections among cisgender women than daily oral PrEP, according to the results of a phase 3 trial.

HIV PrEP uptake has increased sixfold globally in the last 4 years but remains short of the UNAIDS target of 3 million users, according to data reported during the HIV Research for Prevention virtual conference.

An Australian study demonstrated that STI rates among men who have sex with men were high and increasing before they started taking PrEP and remained stable afterward.

Dec. 1 marks the 32nd annual World AIDS Day, which was started to support people living with HIV/AIDS and to commemorate those who have died from the disease.

Only about half of patients who were seen at a sexual health center and subsequently referred to HIV PrEP attended an initial visit, indicating the need to fine-tune the PrEP referral process, researchers reported at IDWeek.

The FDA has granted breakthrough therapy designation status to long-acting, injectable cabotegravir for HIV PrEP, according to ViiV Healthcare.

Teva Pharmaceuticals announced the availability and price of the first generic versions of the HIV medications Truvada and Atripla.

The patent for the HIV medication Truvada expired today, potentially creating an opportunity for a generic PrEP option for patients.

More than 10% of men who have sex with men who use PrEP for HIV prevention reported sharing the medication with others, according to a study published in JAMA Network Open.

The need for HIV PrEP fluctuates as risk behaviors change. In a recent viewpoint published in The Lancet HIV, researchers reviewed current guidelines and the clinical implications of starting, stopping and restarting the daily medication.